[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619103":3},{"organization":4,"outcomesModule":7,"designInfo":57,"detailedDescription":68,"studyPopulation":52,"armGroups":69,"interventions":82,"overallOfficials":52,"centralContacts":91,"locations":97,"responsibleParty":122,"collaborators":52,"id":126,"slug":52,"hasResults":127,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":52,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":132,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":52,"studyType":138,"phases":139,"briefSummary":141,"conditions":142,"keywords":52,"overallStatus":113,"whyStopped":52,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":28,"otherOutcomes":52},[9,13,16,19,22,25],{"measure":10,"description":11,"timeFrame":12},"Change in global blood-oxygen-level-dependent (gBOLD) signal amplitude","The amplitude of the global blood-oxygen-level-dependent (gBOLD) signal was derived from resting-state functional MRI and reflects the overall magnitude of spontaneous brain activity. Unit of Measure: Z-score","2 weeks and 3 months",{"measure":14,"description":15,"timeFrame":12},"Change in resting-state functional connectivity strength","Resting-state functional connectivity strength was calculated as the correlation coefficient between predefined brain regions based on functional magnetic resonance imaging data.",{"measure":17,"description":18,"timeFrame":12},"Change in amplitude of low-frequency fluctuations","Amplitude of low-frequency fluctuations was calculated from resting-state fMRI to quantify spontaneous neural activity.",{"measure":20,"description":21,"timeFrame":12},"Change in regional homogeneity","Regional homogeneity was used to assess the synchronization of local spontaneous brain activity",{"measure":23,"description":24,"timeFrame":12},"Change in phase difference of dynamic cerebral autoregulation","Dynamic cerebral autoregulation was assessed using the phase difference between cerebral blood flow velocity and arterial blood pressure fluctuations. Larger phase differences indicate better autoregulatory function.",{"measure":26,"description":27,"timeFrame":12},"Change in gain of dynamic cerebral autoregulation","Gain represents the magnitude of cerebral blood flow velocity changes in response to blood pressure fluctuations, with lower gain values indicating more effective autoregulation.",[29,32,35,38,41,44,47,50,53,55],{"measure":30,"description":31,"timeFrame":12},"the score of Insomnia Severity Index scale","The total score ranges from 0 to 28, and a higher score indicates higher levels of insomnia severity. A score of 8 or greater is the cut point for clinically possible insomnia",{"measure":33,"description":34,"timeFrame":12},"the score of 14-item Hamilton anxiety rating scale","The total score ranges from 0 to 56, and a higher score indicates higher levels of anxiety symptoms. A score of 7 or greater is the cut point for clinically possible anxiety",{"measure":36,"description":37,"timeFrame":12},"the score of 17-item Hamilton depression rating scale","tThe total score ranges from 0 to 52, and a higher score indicates higher levels of depression symptoms. A score of 7 or greater is the cut point for clinically possible depression symptom",{"measure":39,"description":40,"timeFrame":12},"Change in plasma corticotropin-releasing factor (CRF) level","Plasma corticotropin-releasing factor (CRF) concentration was measured as a biomarker of hypothalamic-pituitary-adrenal (HPA) axis activity. Higher levels indicate increased neuroendocrine stress response. Unit of Measure: pg\u002FmL",{"measure":42,"description":43,"timeFrame":12},"Change in plasma cortisol level","Plasma cortisol concentration was assessed as an indicator of hypothalamic-pituitary-adrenal (HPA) axis function. Higher levels reflect increased physiological stress response. Unit of Measure: μg\u002FdL",{"measure":45,"description":46,"timeFrame":12},"Change in serum interleukin-6 level","Serum interleukin-6 concentration was measured as a marker of systemic inflammation. Higher levels indicate greater inflammatory activity. Unit of Measure: pg\u002FmL",{"measure":48,"description":49,"timeFrame":12},"Change in serum brain-derived neurotrophic factor level","Serum brain-derived neurotrophic factor concentration was measured as a biomarker associated with neuroplasticity and neuronal function. Higher levels indicate enhanced neurotrophic activity. Unit of Measure: pg\u002FmL",{"measure":51,"description":52,"timeFrame":12},"Change in total sleep time (TST) measured by polysomnography",null,{"measure":54,"description":52,"timeFrame":12},"Change in sleep onset latency (SOL) measured by polysomnography",{"measure":56,"description":52,"timeFrame":12},"Change in wake after sleep onset (WASO) measured by polysomnography",{"allocation":58,"interventionModel":59,"interventionModelDescription":52,"primaryPurpose":60,"observationalModel":52,"timePerspective":52,"maskingInfo":61},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":62,"maskingDescription":52,"whoMasked":63},"QUADRUPLE",[64,65,66,67],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Insomnia disorder represents a prevalent clinical challenge, transcranial current stimulation has emerged as a promising noninvasive therapeutic approach; however, its specific effects on neurophysiological mechanisms underlying sleep-related brain structure and functional change, and neurobiological change remain unclear.",[70,76],{"label":71,"type":72,"description":73,"interventionNames":74},"active transcranial current stimulation","ACTIVE_COMPARATOR","14 daily 20-min, 1.1-mA sessions of active or sham transcranial current stimulation, at the beginning and end of treatment, there is a 30 second period of current fading in and out",[75],"Device: transcranial current stimulation",{"label":77,"type":78,"description":79,"interventionNames":80},"sham transcranial current stimulation","SHAM_COMPARATOR","only wore the device and had no stimulation",[81],"Device: Sham stimulation",[83,88],{"type":84,"name":85,"description":86,"armGroupLabels":87,"otherNames":52},"DEVICE","transcranial current stimulation","consecutive daily 20-min, 1.1-mA sessions",[71],{"type":84,"name":89,"description":79,"armGroupLabels":90,"otherNames":52},"Sham stimulation",[77],[92],{"name":93,"role":94,"phone":95,"phoneExt":52,"email":96},"Zan Wang, MD, PhD","CONTACT","+86 88782678","wangzan@jlu.edu.cn",[98,112],{"facility":99,"status":100,"city":101,"state":102,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":111,"contacts":52},"the First Hospital of Jilin University","COMPLETED","Ch’ang-ch’un","Jilin","130021","China","CN",{"type":107,"coordinates":108},"Point",[109,110],126.24667,42.74694,{"lat":110,"lon":109},{"facility":99,"status":113,"city":101,"state":102,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":114,"geoPoint":116,"contacts":117},"RECRUITING",{"type":107,"coordinates":115},[109,110],{"lat":110,"lon":109},[118],{"name":119,"role":94,"phone":120,"phoneExt":52,"email":121},"Zan Wang Prof, PhD","+86-13843025938","wnagzan@jlu.edu.cn",{"type":123,"investigatorFullName":124,"investigatorTitle":125,"investigatorAffiliation":5,"oldNameTitle":52,"oldOrganization":52},"SPONSOR_INVESTIGATOR","Zan Wang","Sleep Center Director","100619103",false,"NCT07340268","The Effects of Transcranial Current Stimulation on Insomnia","Inclusion Criteria:\n\n* Clinical diagnosis of insomnia disorder\n* Cooperate to complete the questionnaire surveys\n\nExclusion Criteria:\n\n* Presence of mental disorders\n* Current use of central nervous system stimulants\n* Use of analgesics,sedatives or hypnotic medications, theophylline preparations, steroid medications\n* Alcohol abuse or regular alcohol consumption\n* Diagnosis of other sleep disorders, including obstructive sleep apnea, rapid eye movement sleep behavior disorder, or restless legs syndrome\n* Sleep disorders secondary to organic diseases, such as epilepsy, diabetes, or renal failure\n* Shift work or irregular work schedules that disrupt normal circadian rhythms\n* Use of medications affecting central nervous system function within the past one month\n* Recent sleep-related confounding behaviors within the past two weeks, including staying up late, alcohol consumption, or smoking\n* Presence of organic brain lesions on head MRI and contraindications to MRI examination",true,"ALL","18 Years","75 Years",{"count":136,"type":137},100,"ESTIMATED","INTERVENTIONAL",[140],"NA","Effect of transcranial current stimulation on insomnia disorder",[143],"Insomnia, Psychophysiological","2026-02-03",{"date":146,"type":147},"2026-02-04","ACTUAL",{"date":149,"type":147},"2026-01-18",{"date":151,"type":137},"2026-12-31",{"name":124,"class":6},2]